Human challenge full-service solution

Unparalleled experience in the design, conduct and analysis of human models of disease

Study design & protocol development

Recruitment

Monitoring

Ethics & regulatory submission

Pharmacy

Data management and biostatistics

Laboratory
support

Biomarker development

Clinical
Study Report

Clinical Trial:
Inpatient or outpatient

Standardised study process

‘Committed to delivering study excellence’


Protocol Design

  • Study management process

  • Services deliver quality results

  • Meeting client needs and timelines

  • Trials conducted using controlled settings and processes


Screening & recruitment

  • Recruitment of volunteers in the UK using the ‘FluCamp’ brand


Quarantine

  • Bespoke quarantine unit in Whitechapel, London for conducting challenge studies: 24 en-suite rooms


Viral Challenge

  • Well characterised challenge

  • Exact exposure time to virus


Intensive sample collections

  • Virology

  • Immunology

  • Biomarkers


Quarantine discharge and follow up

  • Immunugenicity

  • Seroconversion

  • Standard 28 days can be up to 1 year

Other services we offer:

hVIVO Challenge Models

Find out more

Laboratory Services

Find out more

Human Scientific Papers / Abstracts

Rolling Reviews – a useful tool to speed up the regulatory review process

Hot Topics – Vaccine Solutions for Tropical Diseases

Accelerated regulatory pathway for pandemic vaccines

ERS International Congress 2020 Presentation: Experimental Respiratory Syncytial Virus Infection in Adults 60-75 years

Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics

A Key Endpoint in Viral Challenge Models of Asthma Exacerbations

Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model

THE HUMAN VIRAL CHALLENGE MODEL WITH A/PERTH/16/2009 H3N2A SYSTEMATIC ANALYSIS FROM FIVE CLINICAL STUDIES

Scientific Paper 106 – Effect of pre-existing serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults

Scientific paper 49 – An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo